Compare OXBR & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OXBR | MBAI |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Cayman Islands | Israel |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.8M |
| IPO Year | 2014 | 2014 |
| Metric | OXBR | MBAI |
|---|---|---|
| Price | $1.28 | $6.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 22.5K | ★ 70.0K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.78 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,577,000.00 | N/A |
| Revenue This Year | $80.09 | N/A |
| Revenue Next Year | $85.22 | N/A |
| P/E Ratio | $63.50 | ★ N/A |
| Revenue Growth | ★ 371.98 | N/A |
| 52 Week Low | $0.66 | $0.95 |
| 52 Week High | $2.85 | $10.21 |
| Indicator | OXBR | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.45 |
| Support Level | N/A | $1.19 |
| Resistance Level | N/A | $10.21 |
| Average True Range (ATR) | 0.00 | 0.48 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 0.00 | 61.20 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer that provides reinsurance solutions through its subsidiary. The company focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. It specializes in underwriting medium-frequency, high-severity risks where insufficient data exists to effectively analyze the risk/return profile of reinsurance contracts. The company generates revenue from three principal sources: premiums assumed from reinsurance on property and casualty business; income from investments, including unrealized gains or losses on other investments; and income from SurancePlus management fees.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.